US contract sales partnership

AI SummaryClose X

Oxford BioDynamics Plc has partnered with MK Commercial Group to expand its US commercial footprint for its EpiSwitch® PSE prostate cancer diagnostic test, initially deploying seven sales professionals with the potential to scale to 35 representatives. This agreement will extend OBD's reach into key metropolitan markets such as New Jersey, Washington DC, Virginia, Georgia, and the Chicago area, enhancing physician-facing commercial engagement without the fixed costs of a fully employed sales force. The partnership aims to accelerate the adoption of EpiSwitch® PSE by leveraging MKCG's experience in scaling diagnostic businesses.

Disclaimer*

UK 100